Why the study?
While GLP-1RAs improve symptoms and functional capacity in patients with HFpEF and obesity, their effect on outcome and mortality in patients with HF required evaluation.
Does GLP-1RA treatment reduce mortality in patients with heart failure?
Does GLP-1RA treatment reduce mortality in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Real-world evidence suggests GLP-1RA use is associated with reduced cardiovascular mortality in heart failure patients, with the greatest benefit seen in overweight/obese patients with reduced ejection fraction.
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown improved symptomatic relieving and functional capacity in patients with heart failure (HF) with preserved ejection fraction and obesity. OBJECTIVES: The purpose of this study was to evaluate the effect of GLP-1RA on outcome in patients with HF. METHODS: to assess whether GLP-1RA treatment was associated with reduced mortality in patients with HF. RESULTS: and appears to be greater in individuals with an ejection fraction ≤40% compared with >40%. CONCLUSIONS: This nationwide real-world study shows that patients with HF who received GLP-1RA have a significant reduction in CV mortality, which is particularly pronounced in overweight and obese patients with reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
Karlström et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: